^
Association details:
| Biomarker: | FGFR overexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | derazantinib (ARQ 087) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB-C12 - Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer
Published date:
10/29/2019
Excerpt:
An unbiased UC-PDX screen indicated efficacy in 4/17 models (dT/C≤0.4; median=0.81) with DZB-response significantly positively-associated with high FGFR expression.
